Apex Labs Files for US Patent Protecting Psychedelic Drug Delivery System
VANCOUVER, BC, Feb. 14, 2024 /PRNewswire/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the approval by Health Canada of APEX's Controlled Drugs and Substances Dealer's Licence (DL). The DL authorizes APEX to sell psilocybin, including APEX-52 microdose and APEX-90 macrodose psilocybin drug products developed in collaboration with licensed dealers in Canada and the United States. The DL authorizes sale under Health Canada's Special Access Program (SAP). APEX's psilocybin products have previously been used to dose Veteran patients both in clinical trials and through the SAP.
VANCOUVER, BC, Nov. 2, 2023 /PRNewswire/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin treatments is excited to announce the launch of its multi-dose Early Access Program (EAP) for APEX-90 macrodose psilocybin taken in-clinic with assisted psychotherapy. APEX's EAP supports physicians accessing psilocybin through Health Canada's Special Access Program (SAP) and will be rolled out to a select group of Canadian Veteran patients in 2023. The EAP is expected to expand dramatically in 2024 addressing the critical unmet need in depression and PTSD.
VANCOUVER, BC, Aug. 10, 2023 /PRNewswire/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, announces the addition of two new executives to the c-suite, psychiatrist Dr. Mark Johnston, MD, FRCPC, as Chief Medical Officer and Greg Rutherford as Chief Commercial Officer.
VANCOUVER, BC, June 9, 2023 /PRNewswire/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, announces Health Canada Approval of the company's secondary US-based supplier of Good Manufacturing Practices (GMP) psilocybin Active Pharmaceutical Ingredient (API) in addition to its existing primary Canadian-based supplier. APEX is actively shipping drug across the Canadian-US border with permit approvals from Health Canada, the Drug Enforcement Administration (DEA), and US customs.
VANCOUVER, BC, April 20, 2023 /PRNewswire/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, is pleased to announce approval of SUMMIT-90. SUMMIT-90 is a landmark double-blind, placebo controlled phase 2b study evaluating multiple doses of APEX-90 administered in-clinic with assisted psychotherapy for the treatment of severe depression within diagnosed PTSD. The 160 patient trial approval comes by way of a no objection letter received from Health Canada on April 14th, 2023 and the company aims to begin recruitment Q2 of 2023.
Apex Labs (Vancouver, Canada) specialises in bringing psilocybin-derived treatments to market for patients with depression and anxiety in PTSD. They will be starting a randomised, double-blind, placebo-controlled Phase IIb study – APEX-002-A01-03 – to test the safety of APEX-52 for the treatment of anxiety and depression in adults with PTSD.
VANCOUVER, BC, Jan. 19, 2023 /PRNewswire/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company optimizing the standard of mental health care with psilocybin, is pleased to announce its approval by Health Canada to begin APEX-002-A01-03, the world's largest take home psilocybin clinical trial approved to date. This randomized, double-blind, placebo-controlled phase 2b study will evaluate the efficacy, safety and tolerability of APEX-52 microdose, orally administered synthetic psilocybin drug product in treating depression and anxiety among adults diagnosed with Post-Traumatic Stress Disorder (PTSD). The approval comes by way of a No Objection Letter (NOL) from Health Canada received on January 5th 2023.